Literature DB >> 19877064

Interpreting registry-derived drug studies: does societal context matter?

Joel M Kremer, Jeffrey Greenberg.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 19877064     DOI: 10.1002/art.24880

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  5 in total

1.  Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort.

Authors:  Jie Zhang; Ying Shan; George Reed; Joel Kremer; Jeffrey D Greenberg; Scott Baumgartner; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-12       Impact factor: 4.794

2.  Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry.

Authors:  Daniel E Furst; Aileen L Pangan; Leslie R Harrold; Hong Chang; George Reed; Joel M Kremer; Jeffrey D Greenberg
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-06       Impact factor: 4.794

3.  Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.

Authors:  Veena K Ranganath; Paul Maranian; David A Elashoff; Thasia Woodworth; Dinesh Khanna; Theodore Hahn; Catherine Sarkisian; Joel M Kremer; Daniel E Furst; Harold E Paulus
Journal:  Rheumatology (Oxford)       Date:  2013-06-27       Impact factor: 7.580

4.  Malignancy validation in a United States registry of rheumatoid arthritis patients.

Authors:  Mark C Fisher; Victoria Furer; Marc C Hochberg; Jeffrey D Greenberg; Joel M Kremer; Jeff R Curtis; George Reed; Leslie Harrold; Daniel H Solomon
Journal:  BMC Musculoskelet Disord       Date:  2012-05-31       Impact factor: 2.362

5.  The risk for depression in patients with ankylosing spondylitis: a population-based cohort study.

Authors:  Jorit J L Meesters; Ann Bremander; Stefan Bergman; Ingemar F Petersson; Aleksandra Turkiewicz; Martin Englund
Journal:  Arthritis Res Ther       Date:  2014-08-18       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.